Eliem Therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. Backed by RA Capital Management, Access Biotechnology, and Intermediate Capital Group, Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Location: United States, Washington, Redmond
Employees: 11-50
Total raised: $140M
Founded date: 2018
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.05.2021 | Series B | $60M | RA Capital... |
| 25.03.2021 | - | $80M | - |
Mentions in press and media 19
| Date | Title | Description | Source |
| 03.08.2022 | PhIII fail in overall survival measure clouds Ipsen's ex... | In April, Eliem Therapeutics’ lead candidate, ETX-810, failed a Phase II study for diabetic nerve pa... | endpts.com... |
| 18.01.2022 | Eliem Therapeutics Provides Program Updates and an Overview ... | ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigatio... | marketscre... |
| 09.11.2021 | Eliem Therapeutics Reports Third Quarter Financial and Busin... | Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Advanced ETX-155 clinical... | marketscre... |
| 09.11.2021 | Eliem Therapeutics Reports Third Quarter Financial and Busin... | Advanced ETX-155 clinical development program, with the first subject successfully screened in epile... | marketscre... |
| 13.09.2021 | Eliem Therapeutics : Reports Second Quarter Financial Result... | On track to advance two clinical programs through five proof-of-concept trials and progress two prec... | marketscre... |
| 19.07.2021 | Eliem Therapeutics files for IPO as another Seattle-area bio... | Bob Azelby. (Eliem Photo) Eliem Therapeutics, a clinical stage biotech company generating therapies ... | geekwire.c... |
| 24.05.2021 | Eliem raises $60M to take neuro programs to series of data d... | Eliem Therapeutics has raised $60 million to advance treatments for neuronal excitability disorders.... | fiercebiot... |
| 24.05.2021 | INTERMEDIATE CAPITAL GROUP PLC Eliem Therapeutics : Announc... | SEATTLE and CAMBRIDGE, England, May 24, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a clinical-st... | marketscre... |
| 24.05.2021 | Eliem Therapeutics Raises $60M Series B Financing | Eliem Therapeutics., a Seattle, WA- and Cambridge, England, UK-based clinical-stage biotechnology co... | finsmes.co... |
| 24.05.2021 | Seattle neurology startup Eliem Therapeutics raises $60M, tw... | Bob Azelby. (Eliem Photo) New funding: Eliem Therapeutics raised $60 million to further development ... | geekwire.c... |
Show more